tetano
Editor, Senior Moderator
PLoS One
. 2023 Jan 23;18(1):e0280825.
doi: 10.1371/journal.pone.0280825. eCollection 2023.
Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B
João Paulo Portela Catani[SUP] 1 2 [/SUP], Tine Ysenbaert[SUP] 1 2 [/SUP], Anouk Smet[SUP] 1 2 [/SUP], Marnik Vuylsteke[SUP] 3 [/SUP], Thorsten U Vogel[SUP] 4 [/SUP], Xavier Saelens[SUP] 1 2 [/SUP]
Affiliations
Abstract
Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.
. 2023 Jan 23;18(1):e0280825.
doi: 10.1371/journal.pone.0280825. eCollection 2023.
Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B
João Paulo Portela Catani[SUP] 1 2 [/SUP], Tine Ysenbaert[SUP] 1 2 [/SUP], Anouk Smet[SUP] 1 2 [/SUP], Marnik Vuylsteke[SUP] 3 [/SUP], Thorsten U Vogel[SUP] 4 [/SUP], Xavier Saelens[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36689429
- PMCID: PMC9870131
- DOI: 10.1371/journal.pone.0280825
Abstract
Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.